

Table of Contents

Preface	xv
Editorial Comments	xvii
About the Authors	xix
Section I. Routine Tube Methods	1
I-A. Typing for ABO and Rh	2
I-B. Testing for Unexpected Antibodies: LISS Additive Procedure	7
I-C. Crossmatching by LISS Antiglobulin	11
I-D. Weak D Testing Procedure	15
Table I-D-1. Interpretation Recommendations for Direct and Indirect Tests with Anti-D	20
I-E. Crossmatching by Immediate-Spin	21
I-F. Grading and Scoring Serologic Reactions	25
Table I-F-1. Grading Serologic Reactions	28
I-G. Intralaboratory Competency Testing: IAT Reading and Grading Procedure	29
Section II. Antibody Detection	37
II-A. Testing by Albumin Addition/Layering	38
II-B. Testing by Albumin Antiglobulin	41
II-C. Testing by Enzyme Antiglobulin	45
II-D. Testing by LIP Antiglobulin	50
II-E. Testing by LISS Wash Antiglobulin	55
II-F. Testing by LISS-Ficin Antiglobulin	59
II-G. Testing by Polyethylene Glycol Antiglobulin	64
II-H. Testing for Cold-Reactive Antibodies by Direct Agglutination	68
II-I. Testing by Saline Indirect Antiglobulin	71
Section III. Enzyme Techniques	75
III-A. Detecting Antibodies with the Bromelain One-Stage Method	77
III-B. Treating RBCs with α -Chymotrypsin	80

III-C.	Detecting Antibodies with the Ficin One-Stage Method	83
III-D.	Treating RBCs with Ficin	86
III-E.	Treating RBCs with Neuraminidase (T-Activation).	90
III-F.	Detecting Antibodies with the Papain One-Stage Method	93
III-G.	Treating RBCs with Papain	96
III-H.	Treating RBCs with Pronase	100
III-I.	Treating RBCs with Trypsin (Crude Enzyme).	104
III-J.	Treating RBCs with Trypsin (Purified Enzyme)	108
Section IV.	Elution Techniques	113
IV-A.	Washing Before Eluting	114
IV-B.	Eluting Antibodies with Chloroform	116
IV-C.	Eluting Antibodies with Chloroform/Trichloroethylene	120
IV-D.	Eluting Antibodies with Citric Acid	124
IV-E.	Eluting Antibodies with Cold Acid.	128
IV-F.	Eluting Antibodies from Stroma	132
IV-G.	Eluting Antibodies with Ether	136
IV-H.	Eluting Antibodies by Freezing-Thawing (Lui Method).	140
IV-I.	Eluting Antibodies by Freezing-Thawing (Wiener Method)	143
IV-J.	Eluting Antibodies by Heat	147
IV-K.	Eluting Antibodies with Methylene Chloride.	150
IV-L.	Eluting Antibodies with Microwaves	154
IV-M.	Eluting Antibodies from Placental Tissue.	157
IV-N.	Eluting Antibodies Using Ultrasound	160
IV-O.	Eluting Antibodies with Xylene/ <u>D</u> -Limonene	163
IV-P.	Dissociating of IgG with EDTA-Glycine-HCl.	167
IV-Q.	Dissociating of IgG with Chloroquine Diphosphate	170
Section V.	Cell Separation Methods	173
V-A.	Harvesting Autologous RBCs by Direct Centrifugation	174
V-B.	Harvesting Autologous RBCs Using Phthalate Esters.	177
V-C.	Cell Separation Using Percoll-Renografin Procedure	181
V-D.	Harvesting Autologous RBCs in Hemoglobin S or Sickle Cell Disease	184

Table of Contents

V-E.	Separating Mixed-Cell Populations with Antibodies	187
V-F.	Mononuclear Cell Separation Procedure	190
Section VI. Alternative Serologic Methods for Antibody Detection		193
VI-A.	Capillary: Saline Agglutination Procedure	195
VI-B.	Capillary: Albumin One-Layer Procedure	198
VI-C.	Capillary: Albumin Two-Layer Procedure	201
VI-D.	Capillary: Papain One-Stage Procedure	204
VI-E.	Capillary: Ficin One-Stage Procedure	207
VI-F.	Capillary: IAT on Precoated RBCs Procedure	210
VI-G.	Capillary: Precoating for IAT Procedure	213
VI-H.	Microplate: ABO and Rh Typing Procedure	216
VI-I.	Microplate: Antibody Detection Using LISS Procedure	222
VI-J.	Microplate: LIP Technique Procedure	226
VI-K.	Gel: Preparing Buffered Gel Columns	229
VI-L.	Gel: Preparing Anti-IgG Columns	233
VI-M.	Gel: Detecting Antibodies Using Buffered Gel Columns	237
VI-N.	Gel: Detecting Antibodies Using Anti-IgG Columns	240
	Appendix VI-1. Capillary Methods: General Considerations	243
	Appendix VI-2. Microplate Tests: General Considerations	244
	Appendix VI-3. Sephadex Gel Beads: Background Information	246
	Appendix VI-4. Agglutination Reactions in Gel Columns	247
Section VII. Reagent RBCs (Non-Enzyme-Treated)		249
VII-A.	Preparing C3b/C4b-Coated RBCs	250
VII-B.	Preparing IgM/C3b-Coated RBCs	253
VII-C.	Preparing C3b-Coated RBCs: Fruitstone Method	257
VII-D.	Preparing C4b-Coated RBCs	260
VII-E.	Preparing Immunoglobulin-Coated RBCs	263
VII-F.	Preparing IgG-Coated RBCs	267
VII-G.	Treating RBCs: AET Procedure	271
VII-H.	Treating RBCs: DTT Procedure	273
VII-I.	Inactivating S Antigen: Sodium Hypochlorite Treatment	275

VII-J. Freezing RBCs: Glycerol Preservation and Recovery	277
VII-K. Freezing RBCs: Liquid Nitrogen Preservation and Recovery	280
Section VIII. Antibody Identification.	285
VIII-A. Identification of Single or Multiple Antibodies (Process)	286
Figure VIII-A-1. Considerations in investigating unexpected antibodies	290
Figure VIII-A-2. Considerations in investigating blood samples with a positive autocontrol	291
Table VIII-A-1. Serologic Characteristics of Some Alloantibodies to RBC Antigens	292
VIII-B. Management of Samples and Patients with Cold Agglutinins (Process)	294
VIII-C. Evaluation of Panel Results: Crossing Out (Process)	298
Figure VIII-C-1. Antigens crossed out on the top of the antigen profile	300
Figure VIII-C-2. Antigens crossed out on each individual panel cell	300
VIII-D. Selected Cells Process	301
VIII-E. Selection of Antigen-Negative Blood for Transfusion (Process)	304
Table VIII-E-1. Selection of Antigen-Negative Blood for Transfusion	308
VIII-F. Determination of Probability Levels (Process)	309
Table VIII-F-1. Probability Values	313
VIII-G. Acidifying Sera	314
VIII-H. Using a Combined Adsorption/Elution Procedure	316
VIII-I. Detecting Trypsin-Resistant NVG Receptors	320
VIII-J. Using Soluble Blood Group Substances in an Inhibition Procedure	323
Table VIII-J-1. Antibody Inhibition by Blood Group Substances	326
VIII-K. Inhibiting Rouleaux with DIDS	327
VIII-L. Identifying Anti-N _{form}	330
VIII-M. Detecting Complement-Fixing Antibodies by a Two-Stage EDTA-IAT	333
Appendix VIII-1. Evaluation of Initial Antibody Identification Panel	336
Appendix VIII-2. Approaches to Identify/Confirm Antibody Specificity	337
Section IX. Investigating Antibodies to High-Prevalence Antigens	339
Table IX-1. Effect of Papain and Thiol Reagents on Reactions of Antibodies to High-Prevalence RBC Antigens	342
Table IX-2. Effects of Enzymes and Chemicals on Reactions of Antibodies to High-Prevalence RBC Antigens	343

Table of Contents

Figure IX-1. Investigation of antibodies to high-prevalence antigens.	344
IX-A. Inhibiting Antibodies with Pooled Plasma or Serum.	345
IX-B. Identifying Anti-Ch/Rg: Rapid Procedure	348
IX-C. Recognizing Antibodies To HLA Determinants.	351
IX-D. Using Allogeneic C4 for Adsorption of Anti-Ch/Rg.	354
IX-E. Using 2 M Urea for the Screening/Confirmation of Jk(a-b-) RBCs.	357
Section X. Prenatal and Perinatal Testing	361
X-A. Tests During Pregnancy (Process).	367
X-B. Rh Immune Globulin Administration (Process)	370
X-C. Evaluation of HDFN at Delivery (Process).	373
Figure X-B-1. Flow diagram for Rh Immune Globulin administration.	376
X-D. Prenatal Antibody Titration Procedure	377
X-E. Screening for Fetal Rh-Positive RBCs in Maternal Rh-Negative Samples	382
X-F. Quantifying Anti-D with the Enzyme-Linked Antiglobulin Test	386
X-G. Screening for Large Fetomaternal Hemorrhage (Modified Kleihauer-Betke Acid-Elution Test)	391
X-H. Quantifying Fetomaternal Hemorrhage with the Enzyme-Linked Antiglobulin Test.	395
X-I. Analyzing Amniotic Fluid by Spectrophotometry	400
X-J. Treating Cord Blood Contaminated with Wharton's Jelly	404
Section XI. Investigating Samples Containing Autoantibodies.	407
Table XI-1. Specificity of Cold-Reactive Autoantibodies: Comparison of Reactions with Untreated O, I+ RBCs	411
XI-A. Investigation of Cases of Immune Hemolysis and/or a Positive DAT (Process)	412
XI-B. Antiglobulin Testing: Direct Tests with Anti-IgG and Anti-C3	418
XI-C. Antiglobulin Testing: Direct Tests with Anti-IgM and Anti-IgA.	422
XI-D. Antiglobulin Testing: Direct Tests with Polybrene.	425
XI-E. Antiglobulin Testing: Enzyme-Linked DAT	429
XI-F. Dispersing Autoagglutination	433
XI-G. Testing the Thermal Amplitude of a Cold-Reactive Autoantibody	435
XI-H. Diagnostic Testing of a Cold-Reactive Autoantibody by Titration.	438
XI-I. Determining Specificity of a Cold-Reactive Autoantibody by Titration	441

XI-J.	Adsorbing Cold-Reactive Autoantibodies with Autologous RBCs	444
XI-K.	Adsorbing Cold Autoantibodies with Heterologous (Rabbit) RBCs	447
XI-L.	Testing for PCH Using the Donath-Landsteiner Test	451
XI-M.	Determining the Specificity of Warm-Reactive Autoantibodies by Titration	454
XI-N.	Adsorbing Warm-Reactive Autoantibodies with Enzyme-Treated Autologous RBCs	457
XI-O.	Adsorbing Autoantibodies with ZZAP-Treated Autologous RBCs	461
XI-P.	Adsorbing Autoantibodies with ZZAP-Treated Autologous RBCs (Micromethod)	465
XI-Q.	Adsorbing Warm-Reactive Autoantibodies with Allogeneic RBCs	469
Section XII. Investigating Drug-Induced Hemolysis		473
	Table XII-1. Drugs Reported to Cause Immune Hemolysis and a Positive DAT	476
XII-A.	Dissolving Drugs in Solution	480
XII-B.	Preparing Urine for Detecting Metabolite-Dependent Antibodies	487
XII-C.	Detecting Drug-Dependent Antibodies Reacting with Drug-Treated RBCs	490
XII-D.	Detecting Antibodies to Semisynthetic Penicillins	496
XII-E.	Detecting Cephalothin-Dependent Antibodies	500
XII-F.	Detecting Drug-Dependent Antibodies Reacting in the Presence of Drug	503
XII-G.	Detecting Metabolite-Dependent Antibodies Reacting in the Presence of Drug	509
Section XIII. Investigating ABO Typing Problems		515
	Table XIII-1. Causes of ABO Typing Discrepancies	522
	Table XIII-2. Some Anomalous or Uncommon ABO Typing Results	523
	Figure XIII-1. Flow chart for the investigation of ABO discrepancies	524
XIII-A.	Investigation of Mixed-Field Reactions (Process)	525
XIII-B.	Investigation of Nonconcordant ABO Typing Reactions (Process)	527
XIII-C.	Evaluating an ABO Discrepancy	531
XIII-D.	Using Protease-Treated RBCs for ABO Typing Resolution	535
XIII-E.	Confirming Weak A Or B Antigen Expression by Adsorption and Elution	537
XIII-F.	Detecting Minor RBC Populations and ABO Mixtures	541
XIII-G.	Determining ABH Secretor Status	544
XIII-H.	Determining H Antigen Expression	547

Table of Contents

XIII-I. Separating A:O Mixtures	550
XIII-J. Detecting A and B Transferases by Conversion of Group O RBCs	554
XIII-K. Selecting Plasma Containing High-Titer Anti-A and/or Anti-B	557
Section XIV. Investigating RBC Polyagglutination	559
Table XIV-1. Reactions of Polyagglutinable RBCs with Lectins	560
XIV-A. Detecting Polyagglutination with AB and Cord Blood Serum	561
XIV-B. Preparing Crude Extracts of Lectins	564
XIV-C. Preparing Solutions of Purified Lectins	567
XIV-D. Aggregating RBCs with Polybrene	570
XIV-E. Acetylating RBCs	573
XIV-F. Inhibiting Acquired-B Reactivity	577
XIV-G. Testing RBCs with Acidified Anti-B	580
Section XV. Miscellaneous Methods	583
XV-A. Testing for PNH: Acid Hemolysis (Ham's) Test	584
Table XV-A-1. Acid Hemolysis Test Procedure	587
XV-B. Testing for HEMPAS: Modified Acid Hemolysis (Ham's) Test	588
XV-C. Converting IgG Antibodies to Direct Agglutinins	591
XV-D. Assessing RBC Survival Using ⁵¹ Cr-Labeled RBCs	594
XV-E. Differentiating IgM from IgG Antibodies Using DTT	599
Table XV-E-1. Interpretation of 2-ME/DTT Studies to Determine Immunoglobulin Class of Antibody	602
XV-F. Differentiating IgM from IgG Antibodies Using 2-ME	603
XV-G. Performing Dosage Studies Using the Enzyme-Linked Antiglobulin Test	607
XV-H. Predicting Clinical Significance Using the Monocyte Monolayer Assay	612
XV-I. Screening for PNH: Sucrose Hemolysis Test	617
XV-J. Isolating Genomic DNA from Blood	620
XV-K. Converting Plasma to Serum	624
Appendices	627
Index	657